- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | YD Bio Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| YD BIO Aktie jetzt für 0€ handeln | |||||
| 11.08. | YD Bio launches nutrition products via physician partnership model | 2 | Investing.com | ||
| 28.07. | YD Bio launches pilot for cancer testing in British Columbia | - | Investing.com | ||
| 02.07. | YD Bio Limited: YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations | 433 | GlobeNewswire (Europe) | Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 01.05. | YD Bio Limited GAAP EPS of -$0.12, revenue of $0.6M | 4 | Seeking Alpha | ||
| 01.05. | YD Bio Limited Reports Full Year 2025 Financial Results | 175 | GlobeNewswire (Europe) | TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 31.03. | YD Bio launches telehealth platform for cancer detection | 1 | Investing.com | ||
| 26.02. | YD Bio Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.01. | YD Bio Limited: YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation-Driven AI Platforms for Cancer Diagnostics and Drug Development | 335 | GlobeNewswire (Europe) | Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 05.01. | YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap | 573 | GlobeNewswire (Europe) | Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 24.11.25 | YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics | 371 | GlobeNewswire (Europe) | Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 05.11.25 | YD Bio Limited: YD Bio and EG BioMed Expand U.S. Access to OkaiDx, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring | 219 | GlobeNewswire (Europe) | Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 10.10.25 | YD Bio Limited: YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities | 272 | GlobeNewswire (Europe) | Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 28.08.25 | YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market | 373 | GlobeNewswire (Europe) | Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market ExpansionTrading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 113,70 | -24,01 % | Moderna explodiert um 100%, BioNTech um 20%! Was tun? | Moderna explodiert um 100%, BioNTech um 20%! Was tun ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 39,640 | +12,90 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,47 | -2,88 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 38,735 | +3,05 % | Dax lässt nach - Qiagen-Papiere gefragt | Frankfurt/Main - Am Donnerstag hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 25.983 Punkten berechnet, ein Minus in Höhe von 0,4 Prozent im Vergleich zum Vortagesschluss. Nach... ► Artikel lesen | |
| BIONTECH | 94,80 | -2,07 % | BioNTech Aktie: Was der Moderna-Erfolg wirklich bedeutet | ||
| PRAXIS PRECISION MEDICINES | 364,38 | -5,65 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,78 | 0,00 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| NURIX THERAPEUTICS | 27,050 | -2,66 % | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,760 | -2,89 % | Can Asceniv Help ADMA Stock Combat IG Market Challenges? | ||
| ARCUTIS BIOTHERAPEUTICS | 25,360 | -4,45 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,430 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| COGENT BIOSCIENCES | 35,310 | -4,18 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 59,02 | -0,62 % | William Blair startet Coverage für Enliven Therapeutics mit "Outperform" | ||
| RECURSION PHARMACEUTICALS | 3,335 | 0,00 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| STRUCTURE THERAPEUTICS | 50,52 | -6,67 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
YD BIO LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,820 Euro und damit +8,07 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu YD BIO LIMITED finden Sie auf Wallstreet Online.